<DOC>
	<DOCNO>NCT02195050</DOCNO>
	<brief_summary>1 . At target LDL-C level , apoB100 concentration higher recommended level follow population : 1 . Tertiary centre lipid clinic patient raise TG treat statin . 2 . Patients type 2 diabetes treat statin . 3 . Patients Chronic Kidney disease ( CKD ) stag 4 5 treated statin . 2 . Despite achieve LDL-C non-HDL-C target , significant number statin-treated patient residual cardiovascular risk relate raise hsCRP . The relationship hsCRP Lp-PLA2 ( marker inflammation ) LDL particle number measure apoB100 strong measure calculated LDL non-HDL . In statin treat patient high level hs-CRP Lp-PLA2 patient achieve LDL target apo B target . 3 . We hypothesise non-diabetic patient severe hypertriglyceridaemia ( fast serum triglyceride &gt; 5.5 mmol/l ) evidence great nerve damage compare matched control . 4 . LAL deficiency underdiagnosed patient severe hypertriglyceridaemia , low HDL-C , hyperlipidaemia , non alcoholic fatty liver disease idiopathic high liver enzyme .</brief_summary>
	<brief_title>Hypertriglyceridaemia - Cause Effects</brief_title>
	<detailed_description>Fats present body form lipid particle contain cholesterol triglyceride . Lipid particle deposit blood vessel , form atheroma , block blood vessel lead heart attack stroke . These harmful particle term 'atherogenic ' particle . Low density lipoprotein ( LDL ) major atherogenic particle . Each atherogenic particle protein associate call apolipoprotein B ( apoB ) . Cholesterol , triglyceride , apoB level measure laboratory . In study focus patient raise level triglyceride ( hypertriglyceridaemia ) . We recruit patient hypertriglyceridaemia look ( 1 ) therapeutic target , ( 2 ) genetic cause , ( 3 ) associate neuropathy patient . 1 . Therapeutic target arm : LDL-cholesterol ( LDL-C ) primary target lipid-lowering drug . A drug ( commonly statin ) effective lower LDL-C . Patients diabetes , chronic kidney disease hypertriglyceridaemia statins may normal level LDL-C ; size LDL particles patient small , may fact raise level apoB therefore remain cardiovascular risk . Thus , measurement apoB may better target treatment measure 'atherogenic ' particle number . Since atheromatous disease inflammatory disease , also investigate residual risk may correlate inflammatory marker , hsCRP Lp-PLA2 . 2 . Hypertriglyceridaemia nerve function arm : We aim demonstrate severe hypertriglyceridaemia associate significant nerve damage . 3 . Genetic screening arm : Several genetic mutation identify cause hypertriglyceridaemia . Deficiency enzyme lysosomal acid lipase ( LAL ) result Cholesterol Ester Storage Disease ( CESD ) hypercholesterolaemia , hypertriglyceridaemia , abnormal lipid deposition organ . We wish identify genetic mutation associate severe hypertriglyceridemia prevalence LAL deficiency patient attend tertiary referral centre .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Therapeutic target arm Statin treat patient without hypertriglyceridemia . Statin treat patient type 2 diabetes . Statin treat patient CKD stag 4 5 . Nerve function arm â€¢Patients know severe hypertriglyceridaemia ( define triglyceride &gt; 5.5 mmol/l ) know diabetes match control . Genetic screening arm Patients document triglyceride level 10 mmol/l time . Criteria screen FH LAL deficiency include nonobese patient ( BMI &lt; 30 ) low HDLC ( &lt; 1.0 mmol/l male &lt; 1.3 mmol female ) , high triglyceride &gt; 1.7 mmol/l , high total cholesterol &gt; 6.2 LDL cholesterol &gt; 4.7 mmol/l ; patient raise liver alanine aminotransferase ( ALT ) ( 1.5 x ULN ) metabolic viral disease alcohol excess patient diagnose NAFLD without hyperlipidaemia . Pregnant and/or breastfeed woman . Significant liver impairment . Patients know active malignant disease . Patients treated medication could affect lipoprotein metabolism significantly ( like atypical antipsychotic , chemotherapy ) . Untreated hypothyroid hyperthyroidism ( treated TFT normal could recruit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>